MET and renal cell carcinoma: Our findings in RCC demonstrate that DCLK1-IN-1 effectively inhibits the phosphorylation of DCLK1, downregulates key oncogenic and EMT targets (C-Met, C-Myc, and N-Cadherin), impairs colony formation, prevents cell migration and invasion, and inhibits RCC stemness.